Subscribe To
Exact sciences set to rally on positive top-line results from pivotal blue-c study
Exact Sciences (NASDAQ:EXAS) shares rose in Wednesday pre-market trading after the molecular diagnostics company specializing in the detection of earl...
June 21, 2023, 8:14 am
Biomea fusion to present late breaking data from ongoing phase ii trial, covalent-111, evaluating bmf-219 in patients with type 2 diabetes at ada 2023
REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company ...
June 20, 2023, 4:30 pm
Mersana therapeutics announces partial clinical hold on up-next and upgrade-a clinical trials
UPLIFT top-line data expected by early August CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinic...
June 15, 2023, 11:30 am
Plus therapeutics to participate in the 2023 healthcare virtual conference presented by maxim group llc and hosted by m-vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company ...
June 14, 2023, 11:00 am
Aim immunotech to participate in the healthcare virtual conference presented by maxim group llc and hosted by m-vest
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo...
June 14, 2023, 8:45 am
Verastem: updated avutometinib data brings my position out of mothballs
Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment...
June 11, 2023, 4:20 am
Revolution medicines to participate in upcoming investor conferences
REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing target...
June 8, 2023, 4:05 pm
Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
June 8, 2023, 7:30 am
Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
June 8, 2023, 7:30 am
Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
June 8, 2023, 7:30 am
Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
June 8, 2023, 7:30 am
Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
June 8, 2023, 7:30 am
Black diamond therapeutics to present at the jefferies healthcare conference
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology...
June 2, 2023, 12:00 pm
Black diamond therapeutics to present at the jefferies healthcare conference
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology ...
June 2, 2023, 8:00 am
Why shares of genelux corporation jumped this week
Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 tri...
June 1, 2023, 5:19 pm
Viracta therapeutics to present at the jefferies healthcare conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prev...
May 31, 2023, 8:15 pm
Umoja biopharma to present at the 2023 bio international convention
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid...
May 31, 2023, 2:17 pm
Why shares of iovance biotherapeutics jumped tuesday
The FDA set a PDUFA date of Nov. 25 for cell-therapy lifileucel. Iovance focuses on T-cell therapies to treat various ...
May 30, 2023, 4:18 pm
Roche to present new data in blood cancers and solid tumours from its broad portfolio at asco 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer ty...
May 26, 2023, 1:00 am
Plus therapeutics to present at the 2023 virtual june investor summit
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company...
May 25, 2023, 7:00 am